Introduction
Alterations in serotonergic neuronal function in the central nervous system often occur in patients with major depression. 1,2 Recent reviews have summarized the important associations between serotonergic functions and depression. 1, [3] [4] [5] A series of antidepressants, i.e., citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, have been marketed. Selective serotonin reuptake inhibitors (SSRIs) are drugs, which are designed to preferentially increase 5-HT transmission by inhibiting the serotonin transporter (SERT). They have no or only a slight effect on other uptake mechanisms, neurotransmitter receptors, enzymes, etc. These SSRIs have revolutionized the management of depression for millions of patients, and they are widely prescribed for treating various other mental disorders.
Imaging of SERT in humans would provide a useful tool to understand how alterations of this system are related to depressive illness and other psychiatric disorders; therefore, it potentially can benefit millions of patients who are being treated with SSRIs. The first successful radioligand was [ 11 C](+)McN5652 for positron emission tomography (PET) imaging (Chart 1). [6] [7] [8] [9] It showed excellent inhibition of 5-HT reuptake in rat brain synaptosomes (K i ) 0.40 nM for inhibition of SERT) and moderate selectivity toward other monoamine transporters (DAT, dopamine, and NET, norepinephrine transporters; K i ) 23.5 and 1.82 nM, respectively). 10 Specific binding of [ 11 C](+)McN5652 correlates well with the known density of SERT sites in the human brain. 6, [11] [12] [13] Recent reports, using [ 11 C](+)McN5652 for imaging SERT as an indicator of serotonin neurons, have suggested that MDMA (methylenedioxymethamphetamine, "ecstasy") may cause an irreversible decrease of SERT binding sites. 14, 15 (Despite its successful demonstration in imaging SERTs in humans, it has been reported previously that [ 11 C](+)McN5652 has several limitations. 13 ) The uptake in the specific binding area is slow requiring at least 120 min of data acquisition. The nonspecific binding is relatively high, which precludes the measurements of lower SERT density regions. The plasma free fraction is very low (<1%), and it interferes with the kinetic modeling using this tracer.
In search of an improved ligand for SERTs, many compounds have been evaluated (Chart 1). [16] [17] [18] [19] Among these tracers, only [ 123 I]5-iodo-6-nitroquipazine (INQP) [20] [21] [22] showed promising properties for mapping SERT sites in monkey's brain. 23 No human study of [ 123 I]INQP has been reported. Previously, it has been suggested that [ 123 I] -CIT (Chart 1), a SPECT imaging agent, binding to both DAT and SERT, would be able to clarify pathological changes in both dopaminergic and serotonergic systems. However, overlapping uptake regions and differential kinetics of [ 123 I] -CIT binding to DAT and SERT were observed. [24] [25] [26] [27] Nonetheless, the effect of a selective SSRI in human brain in vivo has been directly measured by [ 123 I] -CIT/SPECT imaging of SERT sites in depressed patients undergoing treatment with citalopram. 28, 29 Recently, [ 123 I] -CIT/SPECT imaging showed a significant reduction (30%) of SERT binding in the midbrain area in depressed subjects as compared with controls. 5, [30] [31] [32] A recent report on [ 123 I] -CIT/SPECT imaging of a group of patients suggests that schizophrenia is generally not associated with alterations of DAT in the striatum or SERT in the brainstem. 33 A more selective compound, nor--CIT (Ndemethylated analogue of -CIT), 34 and its related derivatives, 35 have recently been reported as improved SPECT imaging agents for SERT. It is suggested that [ 123 I]nor--CIT might be a suitable alternative tracer for visualization of SERT sites in the human brain with SPECT. 34, 36 However, [ 123 I]nor--CIT still binds to both DAT and SERT, and the selectivity is only marginally improved, not sufficient to distinguish between these two monoamine transporter sites in vivo.
A phenylthiophenyl derivative, 403U76 (Chart 1), was reported as an inhibitor of serotonin and norepinephrine uptake in rat brain synaptosomes (K i ) 2.1 and 55 nM, respectively). No inhibition of dopamine uptake was observed for this series of compounds. 37 It appeared that 403U76 was one of the candidates of antidepressants developed by Glaxo-Wellcome. 38, 39 Surprisingly, no other reports on 403U76 have appeared after 1996. 40 To develop a new SERT selective imaging agent, a series of derivatives based on the substituted phenylthiophenyl core structure were prepared. 41, 42 Methods for synthesis of phenylthiophenyl or the phenoxyphenyl derivatives resulted in different types of coupling reactions to form the desired ring system for developing specific SERT imaging agents. 43 Among the compounds prepared, radioiodinated analogues, IDAM and ADAM (Chart 1), are the most promising candidates for SPECT imaging agents with several attractive properties: high binding affinity and selectivity. 41, 44, 45 In vitro binding studies showed that IDAM displayed an excellent affinity to SERT sites (K i ) 0.097 nM, using membrane preparations of LLC-PK1 cells expressing the specific transporter) and showed more than 1000-fold selectivity for SERT over NET and DAT (expressed in the same LLC-PK1 cells). ADAM also displayed an extremely potent binding affinity toward SERT (K i ) 0.013 nM). It showed more than 1000-fold selectivity for SERT over NET and DAT (K i ) 699 and 840 nM, for NET and DAT, respectively). A preliminary imaging study of [ 123 I]-ADAM in the brain of a baboon by SPECT at 180-240 min post iv injection indicated a specific uptake in the midbrain region rich in SERT. It is apparent that [ 123 I]-ADAM showed a significant improvement over [ 123 I]-IDAM as a SPECT imaging agent for SERT in the brain. 42, 46, 47 Initial imaging studies in humans suggest that the agent clearly localized in the region of hypothalamus region of the brain where the concentration of SERT is the highest (Dr. A. Ahonen, private communication).
A group of 11 C-labeled compounds, based on a similar phenylthiophenyl ring system, was reported, among which DASB, DAPP, AFM, and MADAM showed the most promising properties as PET imaging agents for SERT. [48] [49] [50] Similar to that of IDAM or ADAM, DASB displayed an excellent binding affinity toward SERT (K i ) 1.10 nM), while the binding affinity to the other monoamine transporters was a few 1000-fold lower. After an iv injection in rats, [ 11 C]DASB showed good brain uptake and selective localization in the hypothalamus regions of the brain suggesting selective binding to the SERT. Initial human studies showed that [ 11 C]-DASB had a good brain penetration and localized in the hypothalamus region rich in SERT binding sites. The specific binding in the striatum and hypothalamus regions can be blocked by pretreatment of SSRI, such as paroxetine or citalopram. 49 Subsequently, using the same ligand, it was reported that a significant decrease in striatal SERT binding potential was found after either treatment, as compared to changes found over a 4 week period in healthy subjects. For patients treated with 20 mg/day of paroxetine and citalopram, the mean proportions of SERT sites occupied were 83 and 77%, respectively. [51] [52] [53] A direct measurement of drug occupancy for SSRI on SERT binding sites, an important factor on drug efficacy, 54 was clearly demonstrated by the in vivo imaging technique.
In general, C-11-labeled PET tracers (T 1/2 ) 20 min) have a limited useful window of opportunity for data collection. To improve the feasibility of a full kinetic data analysis and provide a useful alternative PET tracer for imaging SERT with PET, F-18-labeled phenylthiophenyl derivatives were investigated. An initial attempt in preparation of [ 18 F]AFM was reported. 55 To improve the stability of the fluorinated compounds, the fluorine was directly attached to one of the phenyl rings. Reported herein is the synthesis, radiochemistry, and characterization of a novel PET tracer, [ 18 
Chemistry
Preparations of nonradioactive compounds are illustrated in Schemes 1 and 2. 2,5-Dichloro-4-nitrophenylamine (1) was coupled with thiobenzamide 2 to produce a phenylthiophenyl compound 3. The amino group of compound 3 was converted to fluoride 4 by quenching the diazo intermediate with HPF 6 and subsequent thermal decomposition. Nitro and amide groups of fluoride 4 were reduced to amines simultaneously with borane-tetrahydrofuran (THF) to yield 5-chloro-2-(2-dimethylaminomethyl-phenylthio)-4-fluoro-phenylamine (ACF) (5) . A nitro derivative of ACF, 9, was obtained from 3 by a reduction of amide followed by fluorination (Scheme 2). The compound 9 was used as an authentic standard of a potential intermediate of radioactive synthesis.
To obtain [ 18 F]ACF ([ 18 F]5), trimethylammonium salt 7 was prepared as a precursor (Scheme 3), through which the [ 18 F]fluoride displacement was utilized for the radiolabeling reaction. Initially, compound 3 was converted to N,N-dimethylamino derivative 6 by refluxing with methyl iodide and potassium carbonate in dimethylformamide (DMF). The third N-methyl group was introduced by a reaction with methyltriflate to give compound 7, which was highly hygroscopic. However, it was sufficiently pure after several recrystallizations, and it was used directly for the radiolabeling reaction without further purification (Scheme 3). , was purified by a silica cartridge and/or high-performance liquid chromatography (HPLC). The entire procedure required approximately 3 h, and the radiochemical yield (decay corrected) was 15%. The specific activity was 1.0 Ci/mmol (measured by comparing to the diluted cold compound by HPLC by UV detector) at the end of the synthesis (Scheme 4).
Biological Evaluation
In vitro binding assays were performed by using LLC-PK1 cells overexpressing three different types of monoamine transporters (SERT, DAT, or NET, respectively). 56 IDAM, were used. 45, 57 Similar to that observed for the other phenylthiophenyl derivatives, IDAM, ADAM, DASB, and MADAM, the target compound, 5 (ACF), displayed excellent binding affinity to SERT (K i ) 0.05 ( 0.01 nM). Binding affinities to the other monoamine transporters were more than 1000-fold lower, suggesting that ACF is a highly potent and selective ligand for SERT. Two other nitro group-containing intermediates, 3 and 9, also showed good binding affinity and selectivity.
When the no-carrier added [ 18 F]ACF ([ 18 F]5) was injected (iv) into rats, it showed excellent initial brain uptake (3.27 ( 0.79% dose/organ or 1.71 ( 0.45% dose/ g). The tracer also localized in muscle, lungs, and liver, organs where initial blood flow is high (Table 2) .
Regional distribution in the brain showed an expected high uptake and retention in the striatum, hippocampus, and hypothalamus regions, where the serotonin neurons are highly concentrated (Table 2) . It is also observed that the specific uptake for [ 18 F]ACF ([ 18 F]5), in the hypothalamus region, reached the peak between 60 and 120 min after injection as compared to [ 125 I]-ADAM, which reached the peak uptake at 4 h. The relatively fast kinetics of reaching peak uptake is highly desirable for future kinetic modeling study. The ratio of hypothalamus/cerebellum was 3.53 at 60 min and slowly decreased with time. At 4 h after injection, the ratio of hypothalamus/cerebellum was 2.37. In comparison, at 1 h after the iv injection into rats, [ 11 C]DASB showed brain uptake of 0.62% dose/g and a hypothamus/ cerebellum ratio of 8.86. To demonstrate that the uptake of [ 18 F]ACF ([ 18 F]5) in the retention in the striatum, hippocampus, and hypothalamus regions was related to selective SERT, rats were pretreated with specific monoamine transporter inhibitors (McN5652 for SERT, nisoxetine for NET, and methylphenidate for DAT) ( Table 3 ). There were significant changes in the brain regions where the serotonin neurons (SERT) were highly concentrated. There was a significant decrease in specific retention at 60 min in the hypothalamus, striatum, and hippocampus regions after the pretreatment of (+)McN5652 (2 mg/kg at 5 min prior to tracer injection), suggesting that the [ 18 
Experimental Section
IR spectra were recorded on a Mattson Polaris Fourier transform (FT)-IR spectrometer. 1 H and NMR spectra were performed on a Bruker DPX 200 spectrometer using tetramethylsilane as an internal standard. Elemental analyses and mass spectrometries were performed at Department of Chemistry, University of Pennsylvania. THF was distilled immediately before use from sodium benzophenone ketyl. All other chemicals were purchased from Aldrich Chemical Co. and used without further purification. 2-Mercapto-N,N-dimethylbenzamide (2) was prepared by using a reported procedure immediately prior to the reaction and used without purification. 58 
2-(5-Amino-4-chloro-2-nitro-phenylthio)-N,N-dimethylbenzamide (3).
A solution of 1 (3.0 g, 14.5 mmol) and 2 (3.0 g, 16.6 mmol) in DMF (50 mL) was heated to reflux with potassium carbonate (10 g) for 24 h. The mixture was poured into ice water, and the precipitate was collected by a filtration. A dark-colored solid was recrystallized from petroleum ether/ methylene chloride, which yielded 3.8 g of 3 as a pale yellow powder (75%). IR (cm 35 mmol) in water (0.5 mL) was added at -5 to 0°C. To this mixture, 48% hexafluorophosphoric acid (1.5 mL) was added at 0°C and the mixture was stirred for 10 min. The precipitate was collected by filtration. The deep red solid was washed with ice water and air-dried using a suction filter. The solid was further dried under high vacuum for several hours. The red powder was heated at 170°C using an oil bath until gas evolution was no longer observed. A dark-colored residue was purified by 
2-[(2-Amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine (5).
To a solution of 4 (200 mg, 0.56 mmol) in 10 mL of anhydrous THF, 1 N borane-THF complex (10 mL) was added at 0°C under N2. The mixture was heated to reflux for 2 h. After it was cooled to 0°C, 1 mL of concentrated HCl was carefully added and the solvent was removed in vacuo. To the residue, 10 mL of water was added and the mixture was heated to reflux for 20 min. The mixture was cooled, and 1 N NaOH was added to make the pH of the solution basic (pH ∼10). The resulting cloudy aqueous solution was extracted with ethyl acetate (5 mL × 3). The combined organic layer was dried (Na 2SO4), and the solvent was removed in vacuo. The residue was purified by silica gel plate (ethyl acetate) to yield 120 mg of 5 as colorless oil (68%). IR (cm Chloro-5-(dimethylamino)-2-nitro-phenylsulfanyl)-N,N-dimethyl-benzamide (6). Compound 3 (1.0 g, 2. 84 mmol) was heated to reflux with methyl iodide (1.0 g) and potassium carbonate (5 g) in 10 mL of anhydrous DMF for 24 h. The mixture was poured into cold water, and the precipitate was collected by filtration and purified by FLASH40 (Biotage, prepackaged silica column, CH2Cl2/ethyl acetate 5/1) to yield 6 (yellow powder, 0.7 g, 65% -18] activities. The solution was heated at 55°C for 10 min. Water (2 mL) was added, and the mixture was extracted with ethyl acetate (1 mL × 2). The combined organic layer was dried (Na2SO4), and the solvent was removed using an argon stream with gentle heating (55-60°C). The residue was dissolved in CH2Cl2 (2 mL) and injected into a Sep-Pak Plus silica cartridge. The cartridge was washed with 10 mL of CH2Cl2, and eluted activity was discarded. Retained activity was eluted with 5 mL of CH2Cl2/ ethyl acetate 5/1. Solvent was removed using an argon stream with gentle heating. Compound [ 18 F]4 was obtained with a radiochemical purity of 100% (radiochemical yield 80%). Compound [ 18 F]4 was dissolved in THF (0.5 mL), and 0.2 mL of 1 N BH3-THF was added. The mixture was heated at 55°C under argon for 25 min. The solvent was concentrated to near dryness by an argon stream at the end of reaction. To this mixture, 0.4 mL of concentrated HCl and 0.5 mL of ethanol were added with external cooling. To the mixture, 1 mg of SnCl 2 was added and the reaction was kept at room temperature for 20 min. An amount of 5% NaOH (2 mL) was added to the reaction with cooling and extracted with ethyl acetate (2 mL × 2). The combined organic layer was filtered and dried (Na2SO4). The solvent was removed using an argon stream. The residue was dissolved in CH2Cl2 (2 mL) and injected into a Sep-Pak Plus Silica cartridge. The cartridge was washed with CH 2Cl2/ethyl acetate (20/1) 10 mL. Retained activity was eluted with ethyl acetate/MeOH (2/1) 5 mL. The solvent was removed, and [ 18 F]5 was obtained with an RCP of 90%, which was further purified with HPLC (PRP-1 column, CH 3CN/dimethylglutarate buffer (pH 7) 9/1, 1 mL/min, rt ) 8.1 min) to attain RCP >99%. The entire procedure took approximately 3 h, and radiochemical yield was 15% (decaycorrected).
2-(4-
In Vitro Binding. The membrane homogenates of three monoamine transporters (referred to as LLC-DAT, LLC-NET, and LLC-SERT, which were expressed in a common parental cell line LLC-PK1) were prepared and used for the binding assays. Competitive binding assays were performed in a final volume of 0. M) of competing drugs. Nonspecific binding was defined with 10 µM 2 -carbomethoxy-3 -(4-fluorophenyl) tropane (CFT) for DAT and NET assays and 1 µM IDAM for SERT assays. Incubation was carried out for 1 h at room temperature, and the bound ligand was collected on glass fiber filters presoaked with 1% polyethylenimine (Sigma, St. Louis, MO) and counted in a gamma counter (Packard 5000, Downers Grove, IL). Results of competition experiments were subjected to nonlinear regression analysis using EBDA software (Elsevier-BIOSOFT, Cambridge, U.K.).
Biodistribution in Rats. Three rats per group were used for each biodistribution study. While under ether anesthesia, 0.2 mL of a saline solution containing 30 µCi of radioactive tracer was injected into the femoral vein. The rats were sacrificed at the time indicated by cardiac excision while under ether anesthesia. Organs of interest were removed and weighed, and the radioactivity was counted. The percent dose per organ was calculated by comparing the tissue counts to counts of 1% of the initial dose measured at the same time. Regional brain distribution in rats was measured after an injection of the radioactive tracer. Samples from different brain regions (cortex, striatum, hippocampus, cerebellum, and hypothalamus) were dissected, weighed, and counted. The percentage dose/g of each sample was calculated by comparing sample counts with the counts of the diluted initial dose described above.
In vivo competitive binding of various compounds in the regional uptake of [ 18 F]5 was investigated by pretreating animals, respectively, with various competing drugs (2 mg/ kg, each, iv at 5 min prior to injection of [ 18 F]5 50 µCi iv). The competing drugs included methylphenidate, nisoxetine, and (+)McN5652. The reduction of regional brain uptake in the drug-pretreated rats was compared to the control animals with saline pretreatment.
To investigate in vivo metabolism 1 h after an iv injection of 200 µCi of [ 18 F]ACF into three rats, samples of brain, liver, kidney, and blood were removed individually. They were homogenized in 10 volume buffer (50 mM Tris buffer, pH 7.4). The tissue homogenates were extracted with ethyl acetate (3 × 2 mL). Combined ethyl acetate layers were evaporated to near dryness, and the purity of the condensed extracts was analyzed by TLC (silica gel plates, ethyl acetate: MeOH/9:2 v/v). The spots on the TLC plates were counted by Phospor Imager SI (Molecular Dynamics).
Statistics. Effects of drugs on the radioactivity in the various regions of brain after [ 18 F]5 injection were examined using analysis of variance procedures. Data of regional brain uptake of [ 18 F]5 in pretreated rats were compared against those of control rats, using Dunnett's Test for multiple comparisons, with the level of significance set to p < 0.05.
